GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Return-on-Tangible-Asset

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Return-on-Tangible-Asset : 0.65% (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Parnell Pharmaceuticals Holdings's annualized Net Income for the quarter that ended in Dec. 2018 was $0.09 Mil. Parnell Pharmaceuticals Holdings's average total tangible assets for the quarter that ended in Dec. 2018 was $14.22 Mil. Therefore, Parnell Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2018 was 0.65%.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's Return-on-Tangible-Asset or its related term are showing as below:

PARNF's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.8
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Parnell Pharmaceuticals Holdings Return-on-Tangible-Asset Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Return-on-Tangible-Asset Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Return-on-Tangible-Asset
Get a 7-Day Free Trial -57.82 -35.14 -74.58 -100.86 0.65

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Return-on-Tangible-Asset Get a 7-Day Free Trial -46.12 -35.14 -74.58 -100.86 0.65

Competitive Comparison of Parnell Pharmaceuticals Holdings's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Return-on-Tangible-Asset falls into.



Parnell Pharmaceuticals Holdings Return-on-Tangible-Asset Calculation

Parnell Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2018 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=0.093/( (13.788+14.647)/ 2 )
=0.093/14.2175
=0.65 %

Parnell Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2018 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2018 )  (Q: Dec. 2017 )(Q: Dec. 2018 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2018 )  (Q: Dec. 2017 )(Q: Dec. 2018 )
=0.093/( (13.788+14.647)/ 2 )
=0.093/14.2175
=0.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (Dec. 2018) net income data.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Parnell Pharmaceuticals Holdings Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.